52 results about "Clobetasol" patented technology

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

The present invention provides a method for treating psoriasis, by spraying onto the skin with psoriasis daily for at least 4 weeks a pharmaceutical composition containing an effective amount of clobetasol propionate. A preferred pharmaceutical composition containing clobetasol propionate, ethyl alcohol, isopropyl myristate, and anionic surfactant.

A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Topically applicable, anhydrous, hydrophobic and physically/chemically stable dermatological/pharmaceutical oleaginous ointments having effective release/penetration capacity and also having therapeutically effective amounts of calcitriol and clobetasol 17-propionate solubilized therein, are well suited for the treatment of psoriasis.

Topically applicable pharmaceutical compositions useful for the treatment of psoriasis contain respective amounts of calcitriol and clobetasol propionate permitting a once-per-day effective regimen of topical application onto the part or parts of the skin affected by psoriasis.

The present invention relates to stable topical pharmaceutical compositions for the treatment of psoriasis. Disclosed are in particular nonoemulsions comprising nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. These compositions exhibit greater permeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions.

A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with he mouth, such as lichen planus. The formulation includes an aqueous vehicle of based on propylene glycol as a solvent and moisture-retaining agent, and macrogol-glycerol hydroxystearate as a non-ionic emulsifier, being capable of holding surprisingly low concentrations of clobetasol. The vehicle holds concentrations about 0.005% to about 0.05% by weight of 17-clobetasol propionate, more preferably about 0.02 to 0.025%, even more preferably 0.025% by weight of 17-clobetasol propionate. The formulation has a good chemical stability, resulting in a long durability.

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque

A spray foaming dosage form comprising clobetasol propionate, dimethyl isosorbide, propylene glycol, polysorbate, sodium dodecyl sulphate, buffer, optional preservative, optional further excipients, and water.

A pharmaceutical composition comprising: (A) at least one compound of formula (I): wherein X is O or S, preferably O R₆ is H, C_1-6alkyl, —(CH₂)pCOOH, —(CH₂)_pCOOC_1-6alkyl, —(CH₂)_pCONH₂, —(CH₂)_pCONHC_1-6alkyl, —(CH₂)_pCON(C_1-6alkyl)₂, R¹¹ is H or C_1-6 alkyl; each R₅ is —OC_1-10alkyl, —SC_1-10alkyl, —C_1-12alkyl, or OAr²; wherein Ar² is phenyl, optionally substituted with one or more halo; each p is 0 to 3; each z is 1 to 2; or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; and (B) one or more corticosteroid partners, preferably selected from the group consisting of betamethasone, clobetasol, halometasone, dexamethasone, fluocortolone, desoximetasone, diflorasone, fluocinonide, flurandrenolide, halobetasol, amcinonide, halocinonide, triamcinolone, hydrocortisone, aclometasone, fluticasone, mometasone, clocortolone, fluocinolone, desonide, prednisone, prednisolone, and prednicarbate or a pharmaceutically acceptable salt, or a hydrate or solvate thereof, especially betamethasone or a pharmaceutically acceptable salt, or a hydrate or solvate thereof.

The invention discloses an improved production technology of a clobetasol propionate intermediate (betamethasone-17-propionate). Two steps namely cyclo-esterification and hydrolysis in the conventional technology are merged into one step. By merging the steps, the procedure and production period are shortened, the product purity and yield are increased, the energy consumption is reduced, the raw materials and auxiliary materials are saved; the environment pollution is reduced, and the production cost is reduced.

The present invention addresses the problem of providing, in order to treat dermatomycosis accompanying severe inflammations such as flare ups, an externally applied pharmaceutical composition which includes a combination of an anti-fungal agent and a steroidal agent, and in which the anti-fungal agent and the steroidal agent do not interfere with each other. This externally applied pharmaceutical composition for treating mycosis is characterized by including: a compound represented by general formula (1) shown below (in general formula (1), R represents hydrogen or a halogen, and X represents a halogen), and/or a salt thereof; and a steroid selected from prednisolone, dexamethasone, hydrocortisone, clobetasone, clobetasol, betamethasone, and mometasone.

The invention discloses a dandruff-removal composition, which comprises the following components: ketoconazole, clobetasol propionate, vitamin B6, dimethyl sulfoxide, octadecanol, glycerin monostearate, glycerol distearates, cyproheptadine, 2,6-butylated hydroxytoluene and glycerol. Verified by experiments performed by the applicant, the dandruff-removal composition disclosed by the invention is obvious in effect of completely removing dandruffs when being used for dandruff-removal hair care. Moreover, the holding time is long, and dandruffs cannot relapse in at least two years.

The invention discloses a compound clobetasol propionate nano-medicament of which the particle size is 1-100 nanometers. The medicament consists of the following components in percentage by weight: 10.0-50 percent of surfactant, 0-8 percent of cosurfactant, 0.5-20 percent of oil, 0.001-4.0 percent of amitraz, 0.001-4.0 percent of clobetasol propionate, 0.001-10 percent of terbinafine and the balance of distilled water, wherein the total percentage by weight of the components is 100 percent. The medicament has the effects of resisting bacteria, diminishing inflammation, relieving itching and pain, killing mites and treating fungal diseases, eczema and various types of dermatitis caused by fungi such as dermatophyte, microsporosis capitis, acrothesium floccosum, microzyme of monilia and chaff ringworm fungus, and the like. The medicament is a yellow or colorless clear transparent liquid and has the advantages of high stability, high wetting property, good transdermal effect, nontoxicity, non-irritation, high safety, easiness for preparing, low cost and convenience for popularizing.

The present invention relates to a skin disease external application drug, a preparation method and uses thereof, wherein the external application drug is prepared from white vaseline, triethanolamine, zinc oxide, lanolin, glycerin, stearyl alcohol, soft soap, stearic acid, ethylparaben, distilled water, borneol and clobetasol. The preparation method comprises: taking triethanolamine, soft soap, glycerin and ethylparaben, adding distilled water, dissolving, heating to a temperature of 70-80 DEG C, heating an oil phase comprising stearic acid, vaseline, lanolin and stearyl alcohol to a temperature of 80-80 DEG C, adding the water phase to the oil phase, slowly stirring to achieve a temperature of 50 DEG C, and adding borneol and clobetasol to prepare the emulsion. According to the present invention, the external application drug can cure dermatitis, eczema, solarius dermatitis, insect bite dermatitis and psoriasis, has characteristics of good efficacy, no side effect, rapid cure, short cycle, and has effects of anti-inflammation, anti-allergy, and skin protective acidic cortex stabilizing; and the preparation method has characteristics of simple preparation, high efficiency, and wide raw material source.